Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8277205rdf:typepubmed:Citationlld:pubmed
pubmed-article:8277205lifeskim:mentionsumls-concept:C0017387lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C0034760lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:8277205lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:8277205pubmed:issue3lld:pubmed
pubmed-article:8277205pubmed:dateCreated1994-2-8lld:pubmed
pubmed-article:8277205pubmed:abstractTextIn only a few years, the technology of antibody engineering has demonstrated its power and a variety of recombinant monoclonal antibodies are now being developed. Recent developments in gene manipulation have allowed the isolation of antibodies, including human antibodies, with or without immunization, by displaying functional antibody fragments on the surface of bacteriophage particles and directly selecting with antigen. In the present review some recent achievements in these areas are highlighted.lld:pubmed
pubmed-article:8277205pubmed:languageenglld:pubmed
pubmed-article:8277205pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8277205pubmed:citationSubsetIMlld:pubmed
pubmed-article:8277205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8277205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8277205pubmed:statusMEDLINElld:pubmed
pubmed-article:8277205pubmed:issn0393-6155lld:pubmed
pubmed-article:8277205pubmed:authorpubmed-author:CanevariSSlld:pubmed
pubmed-article:8277205pubmed:authorpubmed-author:FurlanDDlld:pubmed
pubmed-article:8277205pubmed:authorpubmed-author:FiginiMMlld:pubmed
pubmed-article:8277205pubmed:authorpubmed-author:MossaAAlld:pubmed
pubmed-article:8277205pubmed:issnTypePrintlld:pubmed
pubmed-article:8277205pubmed:volume8lld:pubmed
pubmed-article:8277205pubmed:ownerNLMlld:pubmed
pubmed-article:8277205pubmed:authorsCompleteYlld:pubmed
pubmed-article:8277205pubmed:pagination147-50lld:pubmed
pubmed-article:8277205pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:meshHeadingpubmed-meshheading:8277205-...lld:pubmed
pubmed-article:8277205pubmed:articleTitleMonoclonal antibodies by genetic engineering: novel reagents for in vivo diagnosis and therapy.lld:pubmed
pubmed-article:8277205pubmed:affiliationDivision of Experimental Oncology E, Istituto Nazionale Tumori, Milano, Italy.lld:pubmed
pubmed-article:8277205pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8277205pubmed:publicationTypeReviewlld:pubmed
pubmed-article:8277205pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed